How do you approach motion management, target margin expansion, and dose constraints when delivering SBRT for refractory ventricular tachycardia?

How do you address challenges of combined cardiac and respiratory motion? Q posted due to recent Red J Publication by Clifford Robinson et al: https://www.redjournal.org/article/S0360-3016(25)06223-6/fulltext